Tukysa Tablet
Product Images NDC 51144-002

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Tukysa (NDC 51144-002). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Seagen Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

150mglabel

This is a prescription drug named TUKYSA (tucatinib) used for medical purposes. Each container contains 60 tablets of 150 mg tucatinib. The recommended dosage should be taken as per the prescribing information. The tablets should be stored at controlled room temperature and should be kept away from children. The unused tablets should be discarded 3 months after opening. This drug is manufactured and trademarked by Seagen Inc. The package has a unique identification number and an expiration date.*

FDA Label Image

2022 03 12

TUKYSA is a drug available in the form of tablets. Each tablet contains tucatinib. The recommended dosage and other important information is available in the prescribing information. The tablets should be stored at a controlled room temperature and should be discarded if unused after three months of opening. TUKYSA is a registered trademark of Sesgen Inc., a subsidiary of Seagen Inc. There is no other useful information for a reader in this text.*

FDA Label Image

50mglabel

Tukysa is a medication that comes in tablet form and is only available with a prescription, containing 50mg of fucatifib per tablet. The recommended dosage should be obtained from the prescribing information. The tablets should be stored in a cool, dry place between 20°C and 25°C (68°F to 77°F); brief excursions are permitted from 15°C to 30°C (59°F to 86°F). Tukysa should be kept in the original container out of the reach of children, with unused tablets discarded three months after the opening. This medicine is a registered trademark of Seagen Inc.*

FDA Label Image

Figure 1 (Fig1)

The text describes a Kaplan-Meier curve graph showing the progression-free survival (PFS) per BICR (Blinded Independent Central Review) in HER2CLIMB, a clinical trial evaluating the efficacy of Tukysa, Tras, and Cape over Pbo, Tras, and Cape in patients with HER2-positive metastatic breast cancer. The x-axis represents the months since randomization, while the y-axis represents the PFS percentage. The text also includes data on the number of patients "at risk" per treatment group at each time point.*

FDA Label Image

Figure 2 (Fig2)

This is a Kaplan-Meier curve which represents the overall survival of patients in the HER2CLIMB clinical trial. The X-axis represents the months since randomization and the Y-axis represents the proportions of patients still alive. The blue line represents the group of patients who received Tukysa+Tras+Cape treatment while the orange line represents the group of patients who received Pbo+Tras+Cape treatment. At each time point, the number of patients at risk is displayed below the graph.*

FDA Label Image

Logo (Logo)

FDA Label Image

Smalllogo

FDA Label Image

Structural Formula (Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.